Dinaciclib and Epirubicin Hydrochloride in Treating Patients With Metastatic Triple-Negative Breast Cancer
Status:
Completed
Trial end date:
2013-09-10
Target enrollment:
Participant gender:
Summary
This phase I clinical trial studies the side effects and the best dose of dinaciclib when
given together with epirubicin hydrochloride (epirubicin) in patients with metastatic (cancer
that has spread to other parts of the body) triple-negative breast cancer. Dinaciclib is
designed to stop cancer cells from dividing into new cancer cells. Epirubicin is designed to
block the way cancer cells grow and divide and may slow or stop cancer cells from spreading
throughout the body. Researchers want to find out what is the highest tolerable dose of the
experimental drug dinaciclib that can be given in combination with epirubicin in patients
with metastatic triple negative breast cancer.